European markets have shown resilience, with the pan-European STOXX Europe 600 Index reaching new highs, buoyed by optimism about the eurozone economy. In this context, penny stocks—typically representing smaller or newer companies—offer intriguing opportunities for investors seeking growth at lower price points. Despite their historical reputation as speculative ventures, many penny stocks today are backed by strong financials and fundamentals, presenting potential value and growth prospects in a rapidly evolving market landscape.
Top 10 Penny Stocks In Europe
| Name |
Share Price |
Market Cap |
Financial Health Rating |
| Orthex Oyj (HLSE:ORTHEX) |
€4.85 |
€86.13M |
★★★★★★ |
| Lucisano Media Group (BIT:LMG) |
€1.04 |
€15.45M |
★★★★★☆ |
| DigiTouch (BIT:DGT) |
€1.94 |
€26.81M |
★★★★★★ |
| Angler Gaming (NGM:ANGL) |
SEK3.60 |
SEK269.95M |
★★★★★★ |
| Angler Gaming (DB:0QM) |
€0.31 |
€222.71M |
★★★★★★ |
| BFF Bank (BIT:BFF) |
€4.306 |
€813.38M |
★★★★☆☆ |
| Libertas 7 (BME:LIB) |
€3.96 |
€84M |
★★★★★☆ |
| High (ENXTPA:HCO) |
€3.59 |
€69.62M |
★★★★★★ |
| Deceuninck (ENXTBR:DECB) |
€2.47 |
€341.41M |
★★★★★★ |
| Netgem (ENXTPA:ALNTG) |
€0.746 |
€24.98M |
★★★★★★ |
Click here to see the full list of 282 stocks from our European Penny Stocks screener.
Let's take a closer look at a couple of our picks from the screened companies.
Impact Developer & Contractor
Simply Wall St Financial Health Rating:★★★★★★
Overview:Impact Developer & Contractor S.A. is a Romanian real estate developer with a market capitalization of RON549.85 million.
Operations:The company's revenue primarily comes from the sale of residential properties, amounting to RON302.65 million, and construction services, which contribute RON143.47 million.
Market Cap:RON549.85M
Impact Developer & Contractor S.A., a Romanian real estate developer, has shown financial resilience with a market capitalization of RON549.85 million and significant revenue streams from residential sales (RON302.65 million) and construction services (RON143.47 million). The company turned profitable this year, reporting net income of RON54.55 million for the nine months ending September 2025, compared to a net loss previously. Despite earnings declining by 10.5% annually over five years, recent profitability is supported by reduced debt levels and strong asset coverage for liabilities. However, earnings were impacted by a large one-off gain of RON84.6 million last year.
Hunter Group
Simply Wall St Financial Health Rating:★★★★★★
Overview:Hunter Group ASA offers oil tanker chartering services through Very Large Crude Carriers (VLCCs) in Norway and has a market capitalization of NOK362.68 million.
Operations:Hunter Group's revenue segment includes developing and operating Very Large Crude Carriers (VLCCs), with a reported revenue of -$5.93 million.
Market Cap:NOK362.68M
Hunter Group ASA, operating in the oil tanker sector, has experienced a financial turnaround with reported third-quarter revenue of US$2.08 million and net income of US$1.65 million, marking a recovery from previous losses. Despite this improvement, the company remains pre-revenue due to its limited sales figures and continues to exhibit high share price volatility compared to Norwegian peers. The firm benefits from being debt-free and having sufficient short-term assets to cover liabilities, but it struggles with profitability challenges as indicated by a negative return on equity of -51.25%. Management stability is notable; however, board experience is relatively low at 2.9 years average tenure.
Heidelberg Pharma
Simply Wall St Financial Health Rating:★★★★☆☆
Overview:Heidelberg Pharma AG is a biopharmaceutical company specializing in oncology and antibody targeted amanitin conjugates (ATAC) with operations in Germany, the United States, and internationally, and has a market cap of €146.89 million.
Operations:The company generates revenue of €3.04 million from its ADC Technology and Customer Specific Research segment.
Market Cap:€146.89M
Heidelberg Pharma AG, operating in the biopharmaceutical sector, has a market cap of €146.89 million and generates €3.04 million in revenue from its ADC Technology and Customer Specific Research segment, yet remains unprofitable with a negative return on equity of -248.59%. The company is debt-free and maintains strong short-term financial health with assets (€41M) exceeding liabilities (€7M). Recent executive changes include the appointment of Dr. Dongzhou Jeffery Liu as CEO, bringing extensive industry experience to the management team. Despite these strengths, Heidelberg Pharma faces challenges with limited cash runway and no immediate path to profitability.
Summing It All Up
-
Click this link to deep-dive into the 282 companies within our European Penny Stocks screener.
-
Seeking Other Investments? We've found 11 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BVB:IMP OB:HUNT and XTRA:HPHA.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
